mTOR抑制剂治疗常染色体显性多囊肾病研究进展
摘要
常染色体显性多囊肾病（ADPKD）是一种以双侧肾脏多发茳行性囊肿增大为主要特征的单基因遗传性疾病。ADPKD多生成年后发病，发病率约为0．05％，具有家族聚集性，男女均可殳病，两性受累机会均等，
出处
《临床内科杂志》
CAS
2013年第8期573-575,共3页
Journal of Clinical Internal Medicine
参考文献20
-
1Vlak MH, Algra A, Brandenburg R, et al. Prevalence of unruptured in- tracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period:a systematic review and meta-analysis. Lancet Neurol, 2011,10:626-636.
-
2Berthier CC, Wahl PR, Le Hir M, et al. Sirolimus ameliorates the en- hanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant,2008,23 : 880-889.
-
3Wolyniec W, Jankowska MM, Krol E, et al. Current diagnostic evaluation of autosomal dominant polyeystie kidney disease. Pal Arch Med Wewn, 2008,118:767-773.
-
4Boletta A. Emerging evidence of a link between the polycystins and the roTOR pathways. Pathogeneties ,2009,2:6.
-
5Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol,2009,20:2493-2502.
-
6Shillingford JM, Piontek KB, Germino GG, et al. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkdl. J Am Soc Nephrol, 2010,21:489-497.
-
7Shillingford JM, Murcia NS, Larson CH, et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sei USA ,2006,103:5466- 5471.
-
8刘春艳,梅长林,袁莉,张懿,付莉莉,蔡厚安,王雪琦.雷帕霉素抑制人多囊肾囊肿衬里上皮细胞增殖及VEGF表达[J].基础医学与临床,2010,30(7):698-702. 被引量：2
-
9Tao Y, Kim J, Schrier RW, et al. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Neph- Iol,2005,16:46-51.
-
10Wahl PR, Serra AL, Le Hir M, et al. Inhibition of mTOR with sirolimus slows disease progression in Han : SPRD rats with autosomal dominant polyeystie kidney disease ( ADPKD ). Nephrol Dial Transplant, 2006, 21:598-604.
二级参考文献8
-
1李慧凛,郑法雷,赵班.雷帕霉素对人肾小管上皮-肌成纤维细胞转化的抑制作用[J].基础医学与临床,2007,27(6):635-642. 被引量：7
-
2Tones VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years [ J ]. Kidney Int, 2009, 76 (2) :149 -68.
-
3Mostov KF. mTOR is out of control in polycystic kidney disease[J]. Proc Natl Acad Sci USA, 2006, 103(14) : 5247 - 5248.
-
4Qian Qi, Du Hui, King BF, et al. Sirolimus reduces polycystic liver volume in ADPKD patients [ J ]. J Am Soc Nephrol, 2008, 19(3) :631 -638.
-
5Loghman-Adham M, Nauli SM, Soto CE, et al. Immortalized epithelial cells from human autosomal dominant polycystic kidney cysts [ J ]. Am J Physiol Renal Physiol, 2003, 285(3): F397 -412.
-
6Zeng G, Taylor SM, McColm JR,et al. Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation[J]. Blood, 2007, 109(4): 1345- 1352.
-
7Elsa BR, Keith H, Srinivasan R. Angiogenesis in autosomal-dominant polycystic kidney disease [ J]. Kidney Int, 2001, 60:37-45.
-
8陆莉,林志彬.一种新型的免疫抑制剂——雷帕霉素[J].中国药学杂志,2001,36(9):643-645. 被引量：28
-
1韩金玉,王秋月.MicroRNA 146的靶分子及其参与的信号通路与肾脏疾病的关系[J].国际泌尿系统杂志,2013,33(6):849-852. 被引量：3
-
2张庆明,沈惠良,雍宜民.腰椎管狭窄症的历史与现状[J].中国骨肿瘤骨病,2005,4(5):307-309.
-
3孙祖玥,赵勇.基因工程在克服移植免疫排斥反应及诱导免疫耐受中的应用[J].中国生物工程杂志,2005,25(1):6-9. 被引量：1
-
4舒运兵,孙广运,杨晓慧.瑞芬太尼复合氯胺酮在小儿短小手术中的应用[J].四川医学,2009,30(6):893-894.
-
5谭最.血管疾病的分子治疗[J].国际外科学杂志,1998,29(1):32-35.
-
6刘旭,张东亮,刘文虎.mTOR抑制剂治疗常染色体显性多囊肾病的研究进展[J].中国全科医学,2010,13(20):2298-2299. 被引量：1
-
7许媛,赵明才.骨关节炎软骨细胞凋亡及其信号通路的研究进展[J].中华临床医师杂志（电子版）,2014,8(6):140-143. 被引量：5
-
8包仕尧,石向群,鲍欢.水通道蛋白4：缺血后脑水肿的靶分子[J].中华脑血管病杂志（电子版）,2007,1(1):4-7.
-
9许书添,姚小丹.多囊肾病发病机制和治疗[J].肾脏病与透析肾移植杂志,2010,19(4):367-372. 被引量：4
-
10张慧君,吴志远.脂类代谢对瘢痕疙瘩作用的研究进展[J].医药前沿,2016,0(7):5-6. 被引量：1
